Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8896375 | 1.00 | TERT (0.42) | TERTPRCPRENDPP7MMP2 | |
| SCHEMBL5752738 | 0.87 | PRCP (0.43) | TERTPRCPRENDPP7TLR2 | |
| SCHEMBL5751421 | 0.87 | PRCP (0.43) | TERTPRCPRENDPP7TLR2 | |
| SCHEMBL19692653 | 0.86 | TERT (0.42) | TERTPRCPDPP7TLR2HTR2C | |
| Hydrochloric Acid SCHEMBL11168293 | 0.82 | PRCP (0.38) | PRCPRENDPP7TLR2HTR2C | |
| SCHEMBL11657843 | 0.81 | TERT (0.42) | TERTPRCPDPP7MMP2 | |
| SCHEMBL10829697 | 0.81 | PSMB5 (0.47) | DPP7MMP2PSMB5 | |
| SCHEMBL10829572 | 0.80 | PSMB5 (0.51) | MMP2PSMB5 | |
| SCHEMBL10829695 | 0.80 | MMP2 (0.35) | MMP2PSMB5 | |
| SCHEMBL11761211 | 0.78 | PRCP (0.42) | TERTPRCPDPP7TLR2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115820441-A | Culture medium for improving tailing condition of candida and fungus drug sensitivity kit | 温州市康泰生物科技有限公司 | 2023-03-21 | — | — | CN | claimed |
| US-20080004223-A1 | DERMATOLOGICAL USES OF THE TRIPEPTIDE MELANOCYTE STIMULATING INHIBITORY FACTOR (MIF) | HLAVKA JOSEPH J | 2008-01-03 | — | — | US | claimed |
| WO-2007137015-A2 | DERMATOLOGICAL USES OF TRI-, TETRA-, PENTA-, AND POLYPEPTIDES | TETRAGENEX PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-4469695-A | 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives | AYERST, MCKENNA & HARRISON, INC. (CA) | 1984-09-04 | — | — | US | claimed |
| US-4469693-A | 2-(4-Substituted alkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives | AYERST, MCKENNA & HARRISON INC. (CA) | 1984-09-04 | — | — | US | claimed |
| US-4469694-A | 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives | AYERST, MCKENNA & HARRISON INC. (CA) | 1984-09-04 | — | — | US | claimed |
| US-4041023-A | Labelled peptides | HOFFMANN-LA ROCHE INC. (US) | 1977-08-09 | — | — | US | claimed |
| US-3931184-A | DISSOLVING IN METHANOL, CRYSTALLIZATION FROM DIETHYL ETHER | ABBOTT LABORATORIES (US) | 1976-01-06 | — | — | US | claimed |
| EP-4097145-B1 | REDUCTION OF ADSORPTION | LEUKOCARE AG (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12350375-B2 | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy | LEUKOCARE AG (DE) | 2025-07-08 | — | — | US | disclosed |
| CN-115820441-B | Culture medium and fungus drug-sensitive kit for improving candida tailing condition | 温州市康泰生物科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20230225939-A1 | MEANS AND METHODS OF STERILIZATION OF BIOFUNCTIONAL COMPOSITIONS | LEUKOCARE AG (DE) | 2023-07-20 | — | — | US | disclosed |
| EP-3511336-B1 | METHOD FOR PREVENTING THE UNFOLDING OF A (POLY)PEPTIDE AND/OR INDUCING THE (RE-)FOLDING OF A (POLY)PEPTIDE | LEUKOCARE AG (DE) | 2023-06-21 | — | — | EP | disclosed |
| CN-115820441-A | Culture medium for improving tailing condition of candida and fungus drug sensitivity kit | 温州市康泰生物科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-0034894-A2 | 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives, processes for their preparation, intermediates used in the processes and the preparation thereof and pharmaceutical compositions containing the derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1981-09-02 | — | — | EP | disclosed |
| EP-0016136-A1 | INHIBITION BY PEPTIDES OF TOLERANCE TO AND DEPENDENCE ON MORPHINE | University of Illinois Foundation (US) | 1980-10-01 | — | — | EP | disclosed |
| WO-1980000216-A1 | INHIBITION BY PEPTIDES OF TOLERANCE TO AND DEPENDENCE ON MORPHINE | UNIV ILLINOIS (US) | 1980-02-21 | — | — | WO | disclosed |
| US-3931184-A | DISSOLVING IN METHANOL, CRYSTALLIZATION FROM DIETHYL ETHER | ABBOTT LABORATORIES (US) | 1976-01-06 | — | — | US | disclosed |
| US-3931184-A | DISSOLVING IN METHANOL, CRYSTALLIZATION FROM DIETHYL ETHER | ABBOTT LABORATORIES (US) | 1976-01-06 | — | — | US | disclosed |
| US-3931184-A | DISSOLVING IN METHANOL, CRYSTALLIZATION FROM DIETHYL ETHER | ABBOTT LABORATORIES (US) | 1976-01-06 | — | — | US | disclosed |